Cambridge Immunology Network
The efficacy of anti-tumour immune responses is reliant on immunogenicity of tumours. Immunogenicity is determined by two main components: antigenicity (presence of neoepitopes that can be presented on MHC class I and recognized by the cytotoxic T cells (CTLs)) and adjuvanticity (presence of signals that will activate antigen presenting cells, such as dendritic cell (DCs), enhancing their capacity to migrate into lymph nodes, license and activate tumour-specific naive T-cells).
We are interested in how tumour-derived signals might regulate functions of dendritic cells, and how cancer cell-dendritic cell interactions can result in immunogenic or tolerogenic responses to tumours. We use co-culture in vitro models to study the communication between cancer cells and dendritic cells, and CRISPR-Cas9 to dissect the pathways governing this communication.
Cambridge Immunology Network Coordinator
University of Cambridge Department of Medicine,
Jeffrey Cheah Biomedical Centre,
Cambridge Biomedical Campus, Puddicombe Way,
Cambridge, CB2 0AW
Follow us on Twitter
Watch our webinars
Sign up to our newsletter
FCEs provide interdisciplinary training programmes for students, fellows and continuing education physicians through FOCIS assisted opportunities
© 2025 University of Cambridge